As global markets experience a rebound fueled by easing core U.S. inflation and strong bank earnings, the focus has shifted to how growth stocks are navigating these conditions. In this environment, companies with substantial insider ownership often attract attention due to their potential alignment of interests between management and shareholders, suggesting confidence in the company's future prospects.
Name | Insider Ownership | Earnings Growth |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
Medley (TSE:4480) | 34.1% | 27.2% |
Plenti Group (ASX:PLT) | 12.7% | 120.1% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 108.3% |
Findi (ASX:FND) | 35.8% | 110.7% |
Click here to see the full list of 1464 stocks from our Fast Growing Companies With High Insider Ownership screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various regions including Europe and the United States, with a market cap of €1.40 billion.
Operations: The company's revenue is primarily derived from its oncology segment, which generated €154.75 million.
Insider Ownership: 11.9%
Earnings Growth Forecast: 55.1% p.a.
Pharma Mar demonstrates potential as a growth company with high insider ownership, highlighted by its forecasted earnings growth of 55.1% annually, outpacing the Spanish market's 8.2%. Despite recent volatility in share price and declining profit margins from 8.3% to 0.4%, it trades at a significant discount to estimated fair value and shows strong revenue growth prospects at 25.5% per year, surpassing the market's expected rate of 4.9%.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Yijiahe Technology Co., Ltd. focuses on the research and development, design, and sale of intelligent robots in China, with a market capitalization of CN¥5.31 billion.
Operations: The company's revenue is derived from its activities in the research, development, design, and sale of intelligent robots within China.
Insider Ownership: 28.2%
Earnings Growth Forecast: 71.6% p.a.
Yijiahe Technology shows promise with forecasted revenue growth of 33.8% annually, significantly outpacing China's market average of 13.4%. Despite recent share price volatility and a net loss of CNY 80.23 million for the first nine months of 2024, the company is expected to achieve profitability within three years. Insider ownership remains stable without substantial buying or selling activity recently, while its return on equity is projected to be relatively low at 3.8%.
Simply Wall St Growth Rating: ★★★★★☆
Overview: KEDE Numerical Control Co., Ltd. manufactures and markets CNC systems and functional components in China, with a market cap of CN¥6.75 billion.
Operations: The company's revenue primarily comes from its General Equipment Manufacturing segment, which generated CN¥540.98 million.
Insider Ownership: 18%
Earnings Growth Forecast: 41% p.a.
KEDE Numerical Control is poised for growth, with earnings forecasted to increase by 41% annually, surpassing the Chinese market's average. Revenue is expected to grow at 38.8% per year. Despite a low future return on equity of 13.7%, analysts agree on a potential stock price rise of 23.1%. Recent earnings show sales reaching CNY 381.34 million and net income at CNY 72.26 million, reflecting solid past performance without recent insider trading activity reported.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include BME:PHM SHSE:603666 and SHSE:688305.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。